Browse the evidence

Understanding the hedonic mechanisms mediated by gut peptide action could advance development of potential therapeutic strategies for the treatment of obesity and its comorbidities.

Research on gut peptides may lead to new obesity treatments.

Active GLP-1 RA prescription was associated with a significant reduction in postoperative hematoma (RR: 0.440; P = 0.023).

Consideration of GLP-1 RA may help in minimizing hematoma risks in surgical patients.

Short-acting GLP-1 receptor agonists are associated with an increased risk of erosive reflux disease (ERD) with a hazard ratio (HR) of 1.215.

Clinicians should be cautious when prescribing short-acting GLP-1 RAs to patients with type 2 diabetes due to the increased risk of ERD.

Short-acting GLP-1 receptor agonists are associated with an increased risk of oesophageal stricture with a hazard ratio (HR) of 1.284.

Healthcare providers should monitor for signs of oesophageal stricture in patients using short-acting GLP-1 RAs.

Short-acting GLP-1 receptor agonists are associated with an increased risk of Barrett's esophagus with dysplasia with a hazard ratio (HR) of 1.505.

Clinicians should be aware of the potential risk of Barrett's esophagus with dysplasia in patients prescribed short-acting GLP-1 RAs.

GLP-1RAs may have renal benefits driven by new-onset macroalbuminuria.

GLP-1RAs may be considered for patients with T2D who also have renal concerns, particularly regarding macroalbuminuria.

Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.

Clinicians should consider the timing of semaglutide administration in relation to elective procedures to mitigate RGC risk.

The contribution of the GIP receptor-activating component of tirzepatide to its effects is uncertain.

Further research is needed to clarify how GIP receptor activation contributes to the effects of tirzepatide.

Baseline muscle protein synthesis (MPS) during androgen deprivation therapy (ADT) is suppressed relative to age-matched controls.

Practitioners should be aware that ADT may lead to reduced muscle protein synthesis in patients.

GLP-1 RAs showed long-term protective effects on renal outcomes and adverse events.

GLP-1 RAs may provide long-term benefits for kidney health in obese individuals without T2D.

In patients with cardiometabolic HFpEF, tirzepatide showed a 58% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Tirzepatide may also be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

Low responders displayed higher plasma leptin levels compared with high responders at baseline.

Understanding leptin levels can help tailor interventions for different responder types.

GLP-1-RAs are known to delay gastric emptying.

Understanding the effect of GLP-1-RAs on gastric emptying is crucial for perioperative management.

GIP accounts for 60% to 80% of the postprandial insulin response.

Understanding GIP's role can help in managing postprandial insulin levels.

GIP is overexpressed in obese individuals, which may exacerbate insulin resistance.

Addressing GIP levels may be important in treating obesity-related insulin resistance.

Baseline HbA1c levels were associated with reduced odds of type 2 diabetes remission after bariatric surgery (pooled difference in means = -1.05, 95% CI = -1.48 to -0.62, p < .001).

Practitioners should monitor HbA1c levels as they may indicate lower chances of remission post-surgery.

Fasting plasma glucose (FPG) levels were associated with reduced odds of type 2 diabetes remission after bariatric surgery (pooled standardized mean difference = -0.42, 95% CI: -0.64 to -0.20, p < .004).

Practitioners should consider FPG levels as a factor that may negatively impact remission rates post-surgery.

The safety profile of tirzepatide was broadly similar across BMI and age subgroups, but drug discontinuation due to adverse events was higher in participants aged ≥ 65 years.

While generally safe, practitioners should monitor older patients closely when prescribing tirzepatide.

Ghrelin is an orexigenic hormone, while GLP-1, GIP, CCK, PYY, and OXM are anorexigenic hormones.

Understanding the roles of these hormones can help in developing targeted interventions for appetite regulation.

Use of second generation oral contraceptives (OC) did not significantly improve muscle adaptations to 10 weeks of resistance training compared with nonusers.

Practitioners should note that second generation OCs do not enhance resistance training adaptations in untrained young women.

Antidiabetic medications can reduce the risk and improve outcomes of cardiovascular diseases.

Consider the cardiovascular benefits when prescribing antidiabetic medications.

New approaches in GLP-1RAs development include multi-agonists and combination therapies.

Practitioners should explore the potential benefits of multi-agonist and combination therapy strategies in GLP-1RA treatments.

Novel GLP-1-based therapeutics are rapidly advancing and may reshape the future landscape of obesity and type 2 diabetes treatment.

Practitioners should consider the potential of these novel agents in treating obesity and type 2 diabetes.

Triple agonists such as retatrutide target GIP, GLP-1, and glucagon receptors to amplify metabolic effects.

Consider the potential of triple agonists in enhancing metabolic outcomes for patients.